Impel Pharmaceuticals Inc.
IMPL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,794% | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 48.7% | -3.4% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -721.4% | -10,538.6% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,023.1% | -11,457.5% | – | – |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| % Growth | -5.3% | -50.1% | -9.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |